Abdominal radiology (New York) · 2025
Imaging findings in fumarate hydratase-deficient renal cell carcinoma: a case series of 11 patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ebisu Naoya, Ueno Yoshiko, Murakami Takamichi, Hyodo Toshiki, Shiraishi Kaori, Nagayama Yasunori, Higaki Atsushi, Tamada Tsutomu, Fujii Mikiya, Fukui Kenichi, Kaga Tesuro, Matsuo Masayuki, Takahashi Satoru, Jinzaki Masahiro
Аннотация
PURPOSE: Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare and aggressive RCC subtype defined in the 2022 WHO classification. This study aimed to describe its imaging and clinicopathological features.
METHODS: A retrospective analysis was conducted on 11 patients (12 tumors) diagnosed with FH-deficient RCC between 2015 and 2024 across multiple institutions. Clinical data, imaging findings (CT, MRI, [18F] fluorodeoxyglucose (FDG) -PET/CT), and histopathological results were reviewed.
RESULTS: The median age at diagnosis was 54 years (range: 35-81), with a male predominance (64%). At presentation, distant metastases were observed in 27% of patients. Based on contrast-enhanced CT findings, tumors were morphologically classified into three types: cystic-predominant (n = 5), solid-predominant (n = 4), and purely solid (n = 3). The dynamic enhancement pattern of the solid components showed progressive enhancement in 54.5% and mild corticomedullary enhancement with delayed washout in 45.5%, suggesting vascular heterogeneity. MRI showed high signal intensity of cystic components on both T1WI and T2WI, suggestive of hemorrhage. Solid components exhibited restricted diffusion on DWI in all cases, with a median ADC value of 0.88 (range: 0.77-1.18) × 10⁻³ mm²/s. On FDG-PET/CT, solid components demonstrated elevated FDG uptake (median SUVmax: 7.25; range: 6.81-10.10). Among nine cases with available follow-up data, three (33%) developed recurrence within two years after surgery.
CONCLUSION: FH-deficient RCC has a high risk of metastasis and recurrence, requiring strict follow-up. Although definitive diagnosis relies on immunohistochemistry, imaging features-such as mixed cystic-solid morphology, hemorrhagic cysts, and, compared with clear cell RCC, lower enhancement, restricted diffusion, and higher FDG uptake-may serve as important diagnostic clues that facilitate accurate pathological diagnosis and management.
METHODS: A retrospective analysis was conducted on 11 patients (12 tumors) diagnosed with FH-deficient RCC between 2015 and 2024 across multiple institutions. Clinical data, imaging findings (CT, MRI, [18F] fluorodeoxyglucose (FDG) -PET/CT), and histopathological results were reviewed.
RESULTS: The median age at diagnosis was 54 years (range: 35-81), with a male predominance (64%). At presentation, distant metastases were observed in 27% of patients. Based on contrast-enhanced CT findings, tumors were morphologically classified into three types: cystic-predominant (n = 5), solid-predominant (n = 4), and purely solid (n = 3). The dynamic enhancement pattern of the solid components showed progressive enhancement in 54.5% and mild corticomedullary enhancement with delayed washout in 45.5%, suggesting vascular heterogeneity. MRI showed high signal intensity of cystic components on both T1WI and T2WI, suggestive of hemorrhage. Solid components exhibited restricted diffusion on DWI in all cases, with a median ADC value of 0.88 (range: 0.77-1.18) × 10⁻³ mm²/s. On FDG-PET/CT, solid components demonstrated elevated FDG uptake (median SUVmax: 7.25; range: 6.81-10.10). Among nine cases with available follow-up data, three (33%) developed recurrence within two years after surgery.
CONCLUSION: FH-deficient RCC has a high risk of metastasis and recurrence, requiring strict follow-up. Although definitive diagnosis relies on immunohistochemistry, imaging features-such as mixed cystic-solid morphology, hemorrhagic cysts, and, compared with clear cell RCC, lower enhancement, restricted diffusion, and higher FDG uptake-may serve as important diagnostic clues that facilitate accurate pathological diagnosis and management.